Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/benzinga.ico', homepage_url='https://www.benzinga.com/', logo_url='https://s3.massive.com/public/assets/news/logos/benzinga.svg', name='Benzinga')•2026-04-02
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis TherapeuticsESPR — Esperion Therapeutics Inc
NASDAQ · Pharmaceuticals · Pharmaceuticals
$1.92-49.21%Market cap670.27M
- Latest Close
- $1.92
- 30-Day Move
- -49.2%
- Market Cap
- $670M
- Shares Outstanding
- 256,810,000
- P/B Ratio
- 81.89
- ROE
- -486.0%
Analyst consensus: Buy · 14 analysts
NASDAQ:ESPRPharmaceuticals / PharmaceuticalsDelayed public snapshot
Esperion Therapeutics Inc
A read-only Alphactor snapshot forEsperion Therapeutics Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$1.92
30-Day Move
-49.2%
Market Cap
$670M
Shares Outstanding
256,810,000
P/B Ratio
81.89
ROE
-486.0%
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$1.92
-49.2%last 90 delayed daily bars
Market cap$670M
90D High
$4.17
90D Low
$1.87
Avg Volume
5,537,841
What stands out
Gross margin is running at 68.0%, which gives a quick read on operating quality before you open the full model.
Net margin is -5.6%, useful for comparing ESPR against peers in Pharmaceuticals.
ESPR is down 49.2% over the last 30 trading days shown on this page.
Latest operating income is $85M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Composite Fair Value
$7.52
Rule of 40
18.1%
Dark Pool Short %
62.7%
Fundamentals snapshot
Latest Close
$1.92
30-Day Move
-49.2%
Market Cap
$670M
Shares Outstanding
256,810,000
P/B Ratio
81.89
ROE
-486.0%
ROA
-4.9%
Gross Margin
68.0%
Operating Margin
14.9%
Net Margin
-5.6%
Debt / Equity
0
Current Ratio
1.54
Latest Revenue
$168M
Financial statement snapshot
Revenue
$168M
Gross Profit
$141M
Operating Income
$85M
Net Income
$62M
Gross Margin
6795.0%
Net Margin
-563.0%
Current Ratio
1.54
Debt / Equity
0.00
Valuation snapshot
Fair Value
$7.52
Upside / Downside
+291.7%
Signal
Undervalued
Implied Growth
--
EV/Rev
$7.52
Growth Assumption
50.0%
Discount Rate
9.6%
Terminal Growth
2.0%
Base FCF
--
Valuation spread
Current Price
$1.92
Composite Fair Value
$7.52
EV/Rev
$7.52
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Negative FCF — company is cash-flow negative. Reverse DCF requires positive cash flows.
Quality snapshot
Altman Z
-2.65
Distress
Piotroski
4
Moderate (4-6)
Cash Conversion
0.58x
Rule of 40
18.1%
Concerning
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $75M | $-180M | $-234M | $-175M |
| 2023-12-31 | $116M | $-156M | $-209M | $-135M |
| 2024-12-31 | $332M | $54M | $-52M | $-24M |
| 2025-12-31 | $403M | $60M | $-23M | $-13M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2026-04-02
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/benzinga.ico', homepage_url='https://www.benzinga.com/', logo_url='https://s3.massive.com/public/assets/news/logos/benzinga.svg', name='Benzinga')•2026-04-02
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/benzinga.ico', homepage_url='https://www.benzinga.com/', logo_url='https://s3.massive.com/public/assets/news/logos/benzinga.svg', name='Benzinga')•2026-03-03
Esperion Acquires Enbumyst Maker CorstasisPublisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2026-02-17
Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040After signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 7,270,216 | 0.03% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 ETF | 5,709,100 | 0.02% | 2026-02-28 |
| WASATCH FUNDS TRUST-Wasatch Ultra Growth Fund | 4,415,356 | 0.02% | 2025-12-31 |
| TIAA-CREF Funds-Nuveen Quant Small Cap Equity Fund | 3,016,380 | 0.01% | 2026-01-31 |
| WASATCH FUNDS TRUST-Wasatch Micro Cap Fund | 2,817,014 | 0.01% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 2,596,223 | 0.01% | 2025-12-31 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 2,266,600 | 0.01% | 2026-01-31 |
| SPDR SERIES TRUST-State Street SPDR S&P Pharmaceuticals ETF | 1,597,799 | 0.01% | 2026-02-28 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
Qube Research & Technologies
Filed 2025-11-14
--
--
Vanguard Group
Filed 2026-01-29
$55M
+23.6%
BlackRock
Filed 2024-08-13
$31M
--
D.E. Shaw
Filed 2026-02-17
$26M
+3208.9%
Geode Capital Management
Filed 2026-02-09
$21M
+20.8%
Marshall Wace
Filed 2026-02-13
$20M
--
Two Sigma Advisers
Filed 2026-02-17
$13M
+83.7%
Goldman Sachs
Filed 2026-02-10
$11M
+66.7%
Dark-pool activity snapshot
Analyst consensus?
Rating(?)
3.93
Consensus
BuyTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
14
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.